In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
Sant P. Chawla, MD
Advertisement
Articles by Sant P. Chawla, MD
Advertisement
Latest Updated Articles
Aldoxorubicin Shows Promise in Advanced Soft-Tissue SarcomaPublished: July 22nd 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma
2
KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma
3
Creating a “Watershed Moment” for Novel Therapeutic Access in Lymphoma
4
Clinical Implications and Future Directions
5
